

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>REGALS CAPITAL MANAGEMENT LP</u> (Last) (First) (Middle) 152 WEST 57TH STREET 9TH FLOOR (Street) NEW YORK NY 10019 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>ORAMED PHARMACEUTICALS INC. [ORMP]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) 10/16/2015	
4. If Amendment, Date of Original Filed (Month/Day/Year)		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock ⁽¹⁾							896,364	I ⁽¹⁾	By Regals Fund LP	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
Call Option (Right to Buy) ⁽¹⁾	\$10	10/16/2015		P		1,192		10/16/2015	05/20/2016	Common Stock	119,200	\$1.1829	1,192	I ⁽¹⁾	By Regals Fund LP
Call Option (Right to Buy) ⁽¹⁾	\$10	10/19/2015		P		600		10/19/2015	05/20/2016	Common Stock	60,000	\$1.1832	1,792	I ⁽¹⁾	By Regals Fund LP
Call Option (Right to Buy) ⁽¹⁾	\$10	10/20/2015		P		11		10/20/2015	05/20/2016	Common Stock	1,100	\$2	1,803	I ⁽¹⁾	By Regals Fund LP

1. Name and Address of Reporting Person* <u>REGALS CAPITAL MANAGEMENT LP</u> (Last) (First) (Middle) 152 WEST 57TH STREET 9TH FLOOR (Street) NEW YORK NY 10019 (City) (State) (Zip)
1. Name and Address of Reporting Person* <u>Regals Fund LP</u> (Last) (First) (Middle) 152 WEST 57TH STREET, 9TH FLOOR (Street)

NEW YORK NY 10019

(City) (State) (Zip)

1. Name and Address of Reporting Person *

Slager David Mark

(Last) (First) (Middle)

152 WEST 57TH STREET, 9TH FLOOR

(Street)

NEW YORK NY 10019

(City) (State) (Zip)

Explanation of Responses:

1. This Form 4 is filed jointly by Regals Fund LP (the "Fund"), Regals Capital Management LP ("Regals Management"), and David M. Slager (collectively, the "Reporting Persons"). Mr. Slager is Managing Member of the general partner of Regals Management. Regals Management is the investment manager of the Fund. The securities reported herein are held for the account of the Fund. Accordingly, each of the Reporting Persons may be deemed to be a beneficial owner of the securities owned by the Fund for purposes of Rule 16a-1(a)(1) under the Securities Exchange Act of 1934, as amended (the "Act"). Pursuant to Rule 16a-1(a)(4) under the Act, Regals Management and Mr. Slager disclaim beneficial ownership in the securities owned by the Fund except to the extent, if any, of their pecuniary interest therein.

Remarks:

/s/ David M. Slager, as
Managing Member of Regals
Capital Holdings LLC, general partner of Regals Capital
Management LP 10/20/2015

/s/ David M. Slager, as
Managing Member of Regals
Fund GP LLC, general partner
of Regals Fund, LP 10/20/2015

/s/ David M. Slager 10/20/2015

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Joint Filer Information

Title of Security: Common Stock

Issuer & Ticker Symbol: ORAMED PHARMACEUTICALS INC. [ORMP]

Designated Filer: Regals Capital Management LP

Other Joint Filers: Regals Fund LP (the "Fund");
David M. Slager

Addresses: The address of each of the Fund and Mr. Slager is 152 West 57th Street, 9th Floor, New York, New York 10019.

Signatures:

Dated: October 20, 2015

REGALS FUND LP
By: Regals Fund GP LLC, its general partner

By: /s/ David M. Slager
Name: David M. Slager
Title: Managing Member

DAVID M. SLAGER

By: /s/ David M. Slager
Name: David M. Slager